– The market for cell therapies of all kinds is exploding in size. By 2025 these regenerative medicines are expected to be a $150 billion market globally with a 30%+ growth rate through the first half of the 2020s according to Roland Berger research. The trouble for the hundreds of companies bringing these new products to market lies in consistent manufacturing. They’re turning to outsourced manufacturing companies as a result
– Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company’s revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners. The company has multiple high-profile clients in the biotechnology …View the full post at: The Unknown Biotech Play That Could Deliver 400% Returns, Or Much More …
Related Articles:
Cannabis Companies Expect Big Growth After Trump Legalizes Hemp
Winning Licenses Quickly Becoming Biggest Advantage for Companies in the Cannabis Sector
The Benefits of CBD in Personal Care Products Presents the Cannabis Sector’s Next Frontier
